Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder characterized by a decline in cognitive abilities and memory impairment, representing the most common form of dementia worldwide.
Why it matters
This review summarizes proposed Alzheimer's mechanisms and new therapeutic modalities such as monoclonal antibodies, ultrasound-based treatments, and biomarker-based diagnostics. It reports no specific treatment result and states that the underlying causes remain incompletely understood, so no cure or prevention is established.
-
28/100
The evidence for cognitive training in preventing cognitive decline in Alzheimer's disease is varied, with some studies indicating cognitive benefits but showing limited impact on functional outcomes or disease progression.
Why it matters
This review found that evidence for cognitive training in preventing cognitive decline in Alzheimer's disease is varied, with some cognitive benefits but limited impact on functional outcomes or disease progression. It does not show that cognitive training prevents or cures Alzheimer's disease.
-
The dominant research paradigm for Alzheimer's disease has focused on amyloid-beta plaqueremoval for over three decades, producing no curative therapy despite billions of dollars ofinvestment.
Why it matters
The paper proposes the Redirection Hypothesis, which reinterprets amyloid accumulation as a late downstream consequence of upstream biological failures rather than the cause of Alzheimer's disease. It is a research proposal and framework, not a tested treatment, cure, or prevention.
-
Alzheimer's disease is a progressive neurodegenerative disorder that significantly impacts memory, cognition, and daily functioning.
Why it matters
This paper presents NeuroCapsule, a system using convolutional neural networks on MRI scans to classify cognitive stages, plus a Digital Memory Vault for storing reminders and personal records. It reports a favorable trade-off between accuracy and computational efficiency on the OASIS dataset, but it is a detection and management tool, not a treatment, cure or prevention.
-
The most successful amyloid-targeting treatments achieve modest plaque reduction with marginal clinical benefit and significant adverse effects.
Why it matters
The paper states that the most successful amyloid-targeting treatments achieve only modest plaque reduction with marginal clinical benefit and significant adverse effects. It offers no new treatment, cure, or prevention data of its own.
-
Introducción. La enfermedad de Alzheimer (EA) es una condición neurodegenerativa progresiva caracterizada por el deterioro cognitivo, la acumulación de beta-amiloide y la neuroinflamación. La tecnología CRISPR/Cas9 ha emergido como una herramienta prometedora para investigar y, potencialmente, tratar la EA, permitiendo ediciones precisas del genoma y la modulación de la expresión génica.
Why it matters
This integrative review reports that CRISPR/Cas9 has been used to create experimental models with human mutations such as in TREM2 and PSEN1, and that correcting a PSEN1 M146L mutation reduced amyloid-beta and restored cellular functions. It notes challenges including off-target mutations and limitations in experimental models, so no treatment or cure in patients is established.
-
Mechanistic studies demonstrate that pharmacological modulation of microglial phenotypes inhibition of pro inflammatory mediators TNF alpha IL 1 IL 6 and targeting pathways such as NF kappa B NLRP3 inflammasome p38 MAPK JAK STAT and TREM2 can attenuate neuroinflammatory cascades and reduce amyloid beta and tau associated neurotoxicity.
Why it matters
This review reports that modulating neuroinflammation reduced amyloid and tau related toxicity in mechanistic studies, but clinical translation remains inconsistent due to problems such as limited brain penetration and patient heterogeneity. It does not show that any neuroinflammation-targeting treatment cures or prevents Alzheimer's disease.
-
Our findings reveal various concerns about Aduhelm involving efficacy, safety, and affordability.
Why it matters
This study examined how caregivers, medical professionals and Reddit users talked about the Alzheimer's drug Aduhelm, finding concerns about efficacy, safety and affordability that increased medical mistrust. It is about social reactions to a drug, not about whether any treatment cures or prevents Alzheimer's disease.
-
This study aimed to assess the diagnostic contribution of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in neurodegenerative dementias presenting with language-predominant symptoms, with or without accompanying behavioral changes, and to evaluate the correspondence between PET-derived metabolic patterns and cerebrospinal fluid (CSF) biomarkers.
Why it matters
In 16 patients with language-predominant dementia symptoms, this study assessed how FDG-PET contributed to diagnosis and how PET metabolic patterns corresponded with cerebrospinal fluid biomarkers. The sample is very small, and the work addresses diagnosis rather than treating, curing, or preventing Alzheimer's disease.
-
Lecanemab and Donanemab are two new FDA-approved antiamyloid immunotherapies that are Alzheimer disease modifying agents.
Why it matters
Lecanemab targets amyloid protofibrils while donanemab targets the amyloid plaque itself, so in theory they could be given together as combination therapy for an augmented effect. Testing this would require competing pharmaceutical companies to work together, which the authors say needs a national agenda.
-
Alzheimer disease (AD) is no longer viewed only as a clinical syndrome of memory impairment but as a biological disease continuum driven by interacting amyloid-β, tau, glial, vascular, metabolic, and synaptic mechanisms.
Why it matters
This review states that amyloid-β monoclonal antibodies have shown that biomarker-confirmed early Alzheimer's disease can be slowed, but the clinical benefit is modest, treatment is restricted to carefully selected patients, and ARIA requires structured monitoring. It proposes a staged, biomarker-guided framework for evaluating other targets such as tau, neuroinflammation and oxidative stress for combination therapy.
-
Early detection of Alzheimer's disease is crucial for effective treatment, and the use of brain MRI images has become a common method for diagnosis.
Why it matters
A pretrained VGG19 CNN combined with SMOTE classified Alzheimer's MRI images with 95% accuracy, higher than a prior VGG-19 result of 77.66%. This is a diagnostic classification method, not a treatment, cure, or prevention.
-
28/100
Alzheimer's disease is a form of progressive dementia that significantly impacts the quality of life of patients and their families.
Why it matters
This study developed a ResNet18-based model that classified Alzheimer's MRI images into four categories with 94.4% accuracy. It is a diagnostic classification tool and does not address treating, curing, or preventing Alzheimer's disease.
-
28/100
The repeated inability of Aβ therapies to pass clinical tests in sporadic AD points to the complexity of the disease and indicates that earlier or more interventions could be necessary.
Why it matters
This hypothetical framework reports that CRISPR/Cas9 editing of APP, PSEN1, BACE1 and APOE4 reduced β-amyloid deposition, decreased tau hyperphosphorylation and improved learning and memory in animal models. It is a proposed therapeutic framework, not an established treatment for people.
-
Alzheimer’s disease is the most common type of dementia, characterized by a progressive decline in cognitive function, particularly memory and impacting daily life.
Why it matters
This is a general review of Alzheimer's disease diagnosis and background, noting that the disease starts earlier in people with Down syndrome. It reports no new findings on treating, curing or preventing Alzheimer's disease.
-
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by memory loss, cognitive decline, and behavioral changes.
Why it matters
Current neuropharmacological treatments for Alzheimer's disease mainly include cholinesterase inhibitors and NMDA receptor antagonists, which aim to relieve symptoms and slow disease progression. New directions focus on disease modification by targeting amyloid and tau pathology, oxidative stress and neuroinflammatory pathways, with monoclonal antibodies and small-molecule inhibitors as possible future therapies.
-
The Early Stages of Alzheimer’s Detection project focuses on identifying signs of Alzheimer’s disease at the earliest possible stage using advanced machine learning and medical imaging techniques.
Why it matters
This project describes a deep learning system that reads MRI brain images and predicts early signs of Alzheimer's, with a web interface for uploading scans. No results from testing the system on patients are reported, so it is not yet evidence that it improves diagnosis or slows the disease.
-
The Early Stages of Alzheimer’s Detection project focuses on identifying signs of Alzheimer’s disease at the earliest possible stage using advanced machine learning and medical imaging techniques.
Why it matters
This project describes a deep learning system that reads MRI brain images and predicts early signs of Alzheimer's, with a web interface for uploading scans. No results from testing the system on patients are reported, so it is not yet evidence that it improves diagnosis or slows the disease.
-
Mit der Einführung neuer Alzheimer-Therapien wie den Anti-Amyloid-Antikörpern Lecanemab und Donanemab rückt ein bislang wenig bekanntes, aber hochaktuelles Phänomen in den Fokus: ARIA – Amyloid-related Imaging Abnormalities.
Why it matters
With the introduction of anti-amyloid antibodies such as lecanemab and donanemab, ARIA (Amyloid-related Imaging Abnormalities) has become an important focus because these MRI findings occur in some treated patients and range from symptomless changes to potentially dangerous complications. This item is an educational talk announcement about recognizing ARIA on MRI, not a study of whether the therapies work.
-
28/100
Neue Alzheimer-Therapien mit Anti-Amyloid-Antikörpern wie Lecanemab oder Donanemab eröffnen Betroffenen neue Chancen – stellen die Radiologie jedoch vor besondere Herausforderungen.
Why it matters
This interview-based article explains that anti-amyloid antibody therapies such as lecanemab and donanemab offer new chances for patients but pose challenges for radiology, especially recognizing and interpreting ARIA on MRI. It is educational guidance for radiologists on imaging findings, risk factors and monitoring, not a study of treatment effectiveness.
-
Alzheimer’s disease is the leading cause of dementia globally and is marked by amyloid-β plaque accumulation, decreased brain pH, disrupted metabolism, and increased permeability of the blood-brain barrier.
Why it matters
In a computer model of microglia metabolism, simulated exercise and metabolic enhancement reduced amyloid-beta plaque accumulation and slowed blood-brain barrier breakdown, but also lowered brain pH. These are model results only and do not show real-world benefit.
-
Corticobasal syndrome (CBS) is a combination of extrapyramidal disorders (asymmetric parkinsonism, dystonia, myoclonia) and cortical disorders (apraxia, disorders of complex types of sensitivity, the alien limb phenomenon).
Why it matters
Two cases are presented in which patients with corticobasal syndrome and Alzheimer-type memory problems had significantly decreased Aβ42 levels in cerebrospinal fluid, which helped establish a diagnosis of Alzheimer's disease. The authors note that biomarkers can help diagnose atypical presentations of Alzheimer's early, which matters both for timely symptomatic treatment and for determining eligibility for anti-amyloid therapy.
-
Introducción: La enfermedad de Alzheimer se considera una de las patologías neurodegenerativas de mayor impacto en la salud pública, con una prevalencia y tasa de mortalidad en incremento.
Why it matters
This systematic review reports that mutations in PSEN1 and PSEN2 are linked to a higher Aβ42/Aβ40 ratio and more amyloid plaque buildup in brain tissue. The authors conclude these mutations may serve as molecular markers for early diagnosis and risk stratification in people with suspected genetic Alzheimer's, though the review itself does not test any treatment.
-
Alzheimer disease (AD) is a pathological worsening process of neurodegenerative disease characterised by impaired thinking, memory and behavioural problems, which have a considerable health impact worldwide.
Why it matters
This review reports that in laboratory and rodent studies curcumin can limit amyloid-beta neurotoxicity, prevent aggregate formation, reduce oxidative and inflammatory injury, and improve cognition and behaviour in animals. It notes limitations such as poor bioavailability, and no disease-altering treatment for Alzheimer's disease currently exists.
-
Apolipoprotein E-4 (APOE-4), serotonin transporter gene (SLC6A4), and single nucleotide polymorphisms (SNPs) of glucocerebrosidase (GBA) are some of the main altered genes in AD, PDD and DLB.
Why it matters
This review describes shared genetic, molecular, and brain-region features among Alzheimer disease, Parkinson disease dementia, and Lewy body dementia, including APOE-4, SLC6A4, and GBA. The authors state further studies are warranted to help differential diagnosis, and no treatment, cure, or prevention is reported.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition
- Elucidating shared genetic signals between type 2 diabetes and three neurodegenerative dementia phenotypes
- A Potential Link Between Visceral Obesity and Risk of Alzheimer's Disease
- Olfactory deficits in Down subjects: a link with Alzheimer disease
- Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies
- The Amyloid Cascade Hypothesis: A Conclusion in Search of Support
- Molecular Basis of Familial and Sporadic Alzheimer's Disease
- Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ42 and T-Tau assays for Alzheimer's disease diagnosis
- Glial cell dysregulation: a new perspective on Alzheimer disease
- LCN2 of cerebrospinal fluid: A potential biomarker for diagnosis and disease progression in Alzheimer's disease